Novartis failed an advanced trial for a muscle disorder disease, and the stock prices of some pharmaceutical company developers fell. SAREPTA THERAPEUTICS fell 11.4% and DYNE THERAPEUTICS fell 22%.

Zhitongcaijing · 3d ago
Novartis failed an advanced trial for a muscle disorder disease, and the stock prices of some pharmaceutical company developers fell. SAREPTA THERAPEUTICS fell 11.4% and DYNE THERAPEUTICS fell 22%.